Bain Capital Life Sciences invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs.

Editas Medicine is a leading genome editing company and part of a transformational new area of health care – genomic medicine. The Company was founded by pioneers and world leaders in genome editing with specific expertise in CRISPR/Cas9 and TALENs technologies. The company’s mission is to translate its proprietary technology into novel solutions to treat a broad range of genetically driven diseases.

Portfolio manager of a market-neutral, diversified healthcare portfolio focused on biotechnology, pharmaceuticals and medical devices stocks.

Analyst for a low net exposure, healthcare-focused hedge fund.

Analyst for a market-neutral healthcare portfolio within a multi-strategy hedge fund. Named a Rising Star of Hedge Funds by Institutional Investor magazine.

Analyst for a long-biased biotechnology hedge fund that also made late-stage private investments.

Sell-side associate and then senior analyst on an equity research team that worked together at two firms.

Started drug discovery platform company that deployed industrial machine learning and novel digital video microscopy technologies to identify and characterize drug candidates in live cells and organisms.